'Depression Electronic Medicine' Wbrain Partners with 'DTx' Meditrix for Business Collaboration

Ybrain announced on the 24th that the two companies have signed a memorandum of understanding (MOU) to collaborate on digital healthcare product businesses, including the depression digital therapeutic device (DTx) developed by Meditrix, a digital medical device specialist company. The core content of this MOU signing is cooperation on the future launch and marketing of the MindChair and depression DTx currently being developed by Meditrix.

Lee Gi-won, CEO of Y-Brain, and Jeon Hong-jin, CEO of Meditrix (Professor of Psychiatry at Samsung Seoul Hospital) (third from the left), along with key executives from both companies, are posing for a commemorative photo at the MOU signing ceremony.
[Photo by Y-Brain]

Meditrix is a digital medical device specialist company founded by Professor Jeon Hong-jin of the Department of Psychiatry at Samsung Seoul Hospital, who has researched depression for 27 years. The MindChair developed by Meditrix combines virtual reality (VR) with a motion chair. It measures the patient's biometric signals in real time on the motion chair to regulate tension and anxiety. It is preparing for approval this year. In addition, Meditrix is developing various products such as a depression DTx that enables home treatment using smartphones and smartwatches, and wellness products that can be purchased without a prescription.

The two companies expect to create business synergy in the field of depression DTx through this partnership. Leveraging Ybrain’s clinical, approval, and marketing expertise accumulated domestically through the depression electronic drug MindStim, they will help industrialize Meditrix’s products, while Ybrain is also expected to expand its DTx lineup and increase its market share in the psychiatry sector.

Jeon Hong-jin, CEO of Meditrix, said, “Through Ybrain’s product development and industrialization know-how, we expect Meditrix’s MindChair and depression DTx to lead the domestic mental health market.” Lee Gi-won, CEO of Ybrain, also stated, “Antidepressants were almost the only treatment for depression, but through the depression electronic drug MindStim, many patients hoping for alternative treatments were able to be guided to hospital treatment. We expect that new and innovative treatment methods like Meditrix’s MindChair will help even more people.”